HIV-1 amino acid changes among participants with virologic failure: Associations with first-line efavirenz or atazanavir plus ritonavir and disease status

Journal of Infectious Diseases

Volumn 206, Issue 12, 2012, Pages 1920-1930

  Mollan, Katie ^a   Daar, Eric S ^b   Sax, Paul E ^c   Balamane, Maya ^d   Collier, Ann C ^e   Fischl, Margaret A ^f   Lalama, Christina M ^a   Bosch, Ronald J ^a   Tierney, Camlin ^a   Katzenstein, David ^d  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CODON; CONTROLLED STUDY; ETHNICITY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BENZOXAZINES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; TREATMENT FAILURE;

EID: 84870223465     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis613     Document Type: Article

References (27)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 10 January 2011:1-166.http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdo lescentGL.pdf. Accessed 19 August 2011.
2. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-26.
3. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-9.
4. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: A systematic review of clinical trials. Clin Infect Dis 2008; 47:712-22.
5. Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapyexperienced patients with HIV infection in North America. Clin Infect Dis 2009; 49:1582-90.
6. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
7. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir- emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-40.
8. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-56.
9. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results. J Infect Dis 2011; 204:1191-201.
10. Winters MA, Coolley KL, Girard YA, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102:1769-75. (Pubitemid 28533822)
11. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-45.
12. Hamming RW. Error detecting and error correcting codes. Bell System Technical Journal 1950; 29:147-60.
13. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-66. (Pubitemid 30426745)
14. Ross LL, Weinberg WG, DeJesus E, et al. Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients. AIDS Res Hum Retroviruses 2010; 26:407-17.
15. Ulbricht KU, Behrens GM, Stoll M, et al. A multicenter, open labeled, randomized, phase III study comparing lopinavir/ritonavir plus atazanavir to lopinavir/ritonavir plus zidovudine and lamivudine in naive HIV-1-infected patients: 48-week analysis of the LORAN trial. Open AIDS J 2011; 5:44-50.
16. Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: Final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199:866-71.
17. Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50:3801-8. (Pubitemid 44684896)
18. Ray JE, Marriott D, Bloch MT, McLachlan AJ. Therapeutic drug monitoring of atazanavir: Surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol 2005; 60:291-9. (Pubitemid 41224137)
19. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-55.
20. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-106. (Pubitemid 351679596)
21. Rhee SY, Kantor R, Katzenstein DA, et al. HIV-1 pol mutation frequency by subtype and treatment experience: Extension of the HIVseq program to seven non-B subtypes. AIDS 2006; 20:643-51. (Pubitemid 43884290)
22. Park SY, Love TM, Nelson J, Thurston SW, Perelson AS, Lee HY. Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS 2011; 25:F13-9.
23. Cousins MM, Laeyendecker O, Beauchamp G, et al. Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One 2011; 6: E27211.
24. Dahirel V, Shekhar K, Pereyra F, et al. From the cover: Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A 2011; 108:11530-5.
25. Kantor R, Wantman M, Katzenstein D, et al. Viral shedding and drug resistance in plasma and genital compartments among viremic, multidrug- experienced HIV-infected men and women. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3-6 February 2008.
26. Carvajal-Rodriguez A, Crandall KA, Posada D. Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy. Infect Genet Evol 2007; 7:476-83. (Pubitemid 46825530)
27. Althaus CL, Bonhoeffer S. Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J Virol 2005; 79:13572-8. (Pubitemid 41508169)